- Conditions
- Hypercholesterolaemia
- Interventions
- alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 2,080
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Episodic Migraine, Chronic Migraine
- Interventions
- Atogepant 60 mg
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 596 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Fresno, California • Los Alamitos, California + 35 more
- Conditions
- Prader-Willi Syndrome
- Interventions
- DCCR, Placebo
- Drug
- Lead sponsor
- Essentialis, Inc.
- Industry
- Eligibility
- 10 Years to 22 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Alzheimer's Disease Psychosis
- Interventions
- ACP-204
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 21
- States / cities
- Costa Mesa, California • Fresno, California • Garden Grove, California + 8 more
- Conditions
- Lennox-Gastaut Syndrome (LGS)
- Interventions
- Placebo, Perampanel
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Gulf Breeze, Florida + 25 more
- Conditions
- Advanced Malignancies
- Interventions
- Tislelizumab, Pamiparib, Temozolomide, Sitravatinib, Ociperlimab, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Anemia
- Interventions
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Jose, California • Boston, Massachusetts + 3 more
- Conditions
- Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
- Interventions
- Setmelanotide
- Drug
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • New York, New York • Marshfield, Wisconsin
- Conditions
- Lipodystrophy
- Interventions
- ISIS 304801, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Autoimmune Encephalitis (AE)
- Interventions
- Efgartigimod PH20 (ARGX-113) SC, Placebo PH20 SC
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Sherman, Texas
- Conditions
- Blood Pressure
- Interventions
- brand name metoprolol ER, Generic A, Generic B
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Gainesville, Florida
- Conditions
- Primary IgA Nephropathy
- Interventions
- LNP023
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • San Diego, California • San Dimas, California + 13 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
- Drug · Procedure
- Lead sponsor
- Ellodi Pharmaceuticals, LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 59
- States / cities
- Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Interventions
- M281, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 29
- States / cities
- Fountain Valley, California • Los Angeles, California • Riverside, California + 24 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, Secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Tuscon, Arizona • Anahiem, California + 13 more
- Conditions
- Alcohol Dependence
- Interventions
- Mirtazapine, Quetiapine fumarate extended release (Quetiapine XR)
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Bedford, New Hampshire • Hanover, New Hampshire
- Conditions
- Safety and Tolerability of Iloperidone
- Interventions
- iloperidone (oral tablet)
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 10
- States / cities
- Costa Mesa, California • North Miami, Florida • Atlanta, Georgia + 7 more
- Conditions
- Hunter Syndrome
- Interventions
- Idursulfase-IT, Elaprase
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 3 Years to 18 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2024
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Chapel Hill, North Carolina • Portland, Oregon + 4 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 54
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
- Conditions
- HIV Infections
- Interventions
- Nevirapine XR, Nevirapine IR
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 11
- States / cities
- Beverly Hills, California • Long Beach, California • Los Angeles, California + 6 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 vaccine, Control
- Biological · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 9 Years to 49 Years · Female only
- Enrollment
- 3,855 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
- Conditions
- Alzheimer's Disease
- Interventions
- simufilam
- Drug
- Lead sponsor
- Cassava Sciences, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Imperial, California • Delray Beach, Florida + 6 more
- Conditions
- Erythropoietic Protoporphyria
- Interventions
- DISC-1459
- Drug
- Lead sponsor
- Disc Medicine, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Francisco, California • Miami, Florida + 7 more
- Conditions
- Chronic Inducible Urticaria
- Interventions
- Remibrutinib, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more